A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development.
The abstract entitled ‘Interim Safety and Efficacy Data from a Phase 1 Clinical Trial of Sustained-release Axitinib Hydrogel Implant (OTX-TKI) in Wet AMD Subjects’ was presented at the American Academy of Ophthalmology (AAO) meeting in Chicago, USA, 30 September – 3 October 2022.
- What are the limitations of intravitreal injections of anti-vascular endothelial growth factor agents in the treatment of wet age-related macular degeneration? (0:20)
- What is OTX-TKI and what are its potential advantages? (1:23)
- What were the aims, design and eligibility criteria of the study you presented? (2:11)
- What were the interim efficacy and safety findings? (3:21)
- What will be the next steps in the clinical development of OTX-TKI? (5:09)
Disclosures: Dilsher Dhoot is on the advisory board, a consultant for and has received honoraria from Alimera Sciences, Allergan, Apellis, Bausch and Lomb, Bayer, Coherus, Eyepoint, Genentech, Novartis, Regeneron, RegenXBio and Roche. He has received grant or research support from Allergan, Genentech and Regeneron and is on the speaker’s bureau for Alimera, Apellis, Eyepoint, Genentech and Regeneron.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of AAO 2022
Access more content on Macular Degeneration here
Share this Video
Related Videos In Macular Degeneration
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Rahul Khurana, AAO 2022: Loss to follow-up in patients with nAMD treated with anti-VEGF therapy in the US
Dr Rahul Khurana (Northern California Retina Vitreous Associates, Mountain View, CA, USA) took part in a retrospective cohort study investigating the incidence of loss to follow-up after anti–vascular endothelial growth factor (VEGF) injections among patients with neovascular age-related macular degeneration. In this interview, he discusses with touchOPHTHALMOLOGY the design and findings of this study as […]
Francesco Bandello, EURETINA 2022: The Relationship Between OCTA and FA/ICGA in AMD Part 1
In this touchOPHTHALMOLOGY interview, Prof. Francesco Bandello (Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele, Milan, Italy) talks us through the advantages of optical coherence tomography angiography (OCTA) over conventional dye angiography in age-related macular degeneration (AMD) and a study investigating the relationship between OCTA and fluorescein angiography/indocyanine green angiography in AMD. ‘Morphological and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!